TMB and various biomarkers were positively associated with improved pCR and EFS in high-risk, early-stage TNBC, regardless of ...

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Lenvatinib plus pembrolizumab did not improve PFS or OS over chemotherapy in patients with advanced or recurrent endometrial ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Unlike existing and first-generation immunotherapies that exclusively target immune T cells, these monoclonal antibodies are engineered to precise ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

FYB-206 is under development for the treatment of malignant melanoma (black skin cancer) and non-small cell lung cancer. The drug candidate is a pembrolizumab biosimilar. It acts by targeting ...

However, results from the randomized KEYNOTE-522 study showed an improvement in overall survival (OS) in patients with stage II-III TNBC who received pembrolizumab (Keytruda) before and after ...

The findings, published in The Lancet, establish pembrolizumab as a new option for patients with this disease. "Soft tissue sarcoma is a rare and complex disease with over 50 different subtypes ...